耳鼻咽喉科・頭頸部外科86巻1号

2014年01月発行

特集 耳鼻咽喉科・頭頸部外科領域の最新トピックス

≪頭頸部腫瘍領域≫

抗EGFR抗体薬の作用機序と開発状況

著者： 岡野晋¹

所属機関： ¹東京慈恵会医科大学耳鼻咽喉科学教室

ページ範囲：P.88 - P.92

文献概要

POINT

●抗EGFR抗体薬は細胞の分化・増殖などにかかわる受容体をブロックすることにより効果を発揮する。

●抗腫瘍効果には，ADCC活性，CDC活性なども関与している。

●セツキシマブのほかにも多くの抗体薬を用いた臨床試験が進行中であり，その有効性が検証されている。

参考文献

1）Carpenter G, et al：Characterization of the binding of 125-I-labeled epidermal growth factor to human fibroblasts. J Biol Chem 250：4297-4304, 1975

2）Jorissen RN, et al：Epidermal growth factor receptor：mechanisms of activation and signalling. Exp Cell Res 284：31-53, 2003

3）Ramsauer VP, et al：Muc4/sialomucin complex, the intramembrane ErbB2 ligand, translocates ErbB2 to the apical surface in polarized epithelial cells. J Biol Chem 278：30142-30147, 2003

4）Shimodaira H, et al：Antibody-dependent cellular cytotoxicity in the immunotherapeutic mechanisms of anti-EGFR monoclonal antibody. Gan To Kagaku Ryoho 37：795-798, 2010

5）Isturiz MA, et al：Two different Fc gamma receptor-dependent cytotoxic mechanisms triggered by monoclonal immunoglobulins. Immunol Lett 29：271-275, 1991

6）Bonner JA, et al：Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354：567-578, 2006

7）Bonner JA, et al：Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer：5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11：21-28, 2010

8）Ang KK：A randomized phase Ⅲ trial（RTOG 0522）of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage Ⅲ-Ⅳ head and neck squamous cell carcinomas（HNC）［abstract no. 5500］. J Clin Oncol 30, 2011

9）Burtness B, et al：Phase Ⅲ randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer：an Eastern Cooperative Oncology Group study. J Clin Oncol 23：8646-8654, 2005

10）Vermorken JB, et al：Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359：1116-1127, 2008

11）Vermorken JB, et al：Open-label, uncontrolled, multicenter phase Ⅱ study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 25：2171-2177, 2007

12）Baselga J, et al：Phase Ⅱ multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 23：5568-5677, 2005

13）Herbst RS, et al：Phase Ⅱ multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 23：5578-5587, 2005

14）Giralt J：A phase Ⅱ, randomized trial（CONCERT-1）of chemoradiotherapy（CRT）with or without panitumumab（pmab）in patients with unresected, locally advanced squamous cell carcinoma of the head and neck［abstract no. 5502］. J Clin Oncol 30（Suppl）, 2012

15）Vermorken JB, et al：Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck（SPECTRUM）：an open-label phase 3 randomised trial. Lancet Oncol 14：697-710, 2013

16）Stoehlmacher-Williams J：Safety and efficacy of panitumumab in HPV-positive and HPV-negative recurrent/metastatic squamous cell carcinoma of the head and neck：analysis of the global phase Ⅲ SPECTRUM trial［abstract no. 5504］. J Clin Oncol 30（Suppl）, 2012

17）Machiels JP, et al：Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy：an open-label, randomised phase 3 trial. Lancet Oncol 12：333-343, 2011

18）Rodriguez MO, et al：Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck. Cancer Biol Ther 9：343-349, 2010

19）Ramakrishnan MS, et al：Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. MAbs 1：41-48, 2009

20）Babu K：An open-label, randomized, study of h-R3mAb（nimotuzumab）in patients with advanced（stage Ⅲ or Ⅳa）squamous cell carcinoma of head and neck（SCCHN）：four-year survival results from a phase Ⅱb study［abstract no. 5530］. J Clin Oncol 28（Suppl）, 2010